FDA Nearing Approval of Highly Addictive New Opioid
In a controversial move, the U.S. Food and Drug Administration (FDA) is moving toward finalizing the approval of a highly addictive opioid. The decision was made by the FDA's advisory committee on October 12, where a 10–3 vote occurred in favor of the drug hitting the market.
"We are pleased with the Advisory Committee's recommendation to approve DSUVIA as a treatment in medically supervised settings for adults experiencing moderate-to-severe acute pain," Dr. Pamela Palmer, Co-Founder and Chief Medical Officer of AcelRx said in a news release. "We look forward to continued collaboration with the FDA on the application as we believe DSUVIA represents an important non-invasive acute pain management option with potential to significantly improve the current standard of care."
DSUVIA, the drug in question, is a form of Sufentanil—which is more potent than fentanyl and morphine. It would be sold as an under-the-tongue tablet. While it can treat pain, it's associated with a high risk for addiction and being dependent upon it. Side effects include but aren't limited to restlessness, muscle spasms, chest pain and fast heartbeat, according to PubMed Health.
https://www.msn.com/en-us/news/us/fda-nearing-approval-of-highly-addictive-new-opioid/ar-BBOErl0?ocid=spartanntp
note in pic: designed in collaboration with the DoD, specifically designed to target those needle phobic